July 2003 in “Journal of Cutaneous Medicine and Surgery” Treating psoriasis with UVB light three times a week is faster than twice a week, and certain medications and lifestyle factors affect psoriasis treatment outcomes.
July 2003 in “Journal of Cutaneous Medicine and Surgery” Skin problems are common in Bangladesh due to arsenic, prompt treatment of diabetic foot ulcers is crucial, maternal transmission causes most neonatal herpes, treatments for pediatric vasculitis are effective, the chickenpox vaccine works, more frequent UVB therapy helps psoriasis, certain jobs increase hand dermatitis risk, monoclonal antibodies treat psoriasis well, lifestyle affects psoriasis, alefacept improves psoriasis, imiquimod cream partially clears basal cell carcinoma, and iron may not help chronic hair loss.
July 2003 in “Journal of Cutaneous Medicine and Surgery” Blood pressure drugs can cause skin lupus, but it improves after stopping the drug. The glycoprotein D vaccine works against genital herpes in some women, and the HPV-16 vaccine reduces HPV-16 infection and related diseases. More frequent light therapy clears psoriasis faster. A cream called imiquimod effectively treats a type of skin cancer. Iron supplements don't necessarily help with chronic hair loss in women.
July 2003 in “Journal of Cutaneous Medicine and Surgery” Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.
January 2003 in “American Journal of Clinical Dermatology” In 2002, various skin reactions were reported due to different drugs, including allergies, hair loss, skin lesions, and other skin conditions.
126 citations
,
April 2015 in “Clinical, cosmetic and investigational dermatology” Choosing the right patients, using proper techniques, and having thorough knowledge are key to preventing and managing dermal filler complications.
59 citations
,
November 2018 in “Psychoneuroendocrinology” Lower levels of certain brain chemicals are linked to worse PTSD symptoms in men.
33 citations
,
August 2006 in “Journal der Deutschen Dermatologischen Gesellschaft” Pregnancy can cause specific skin conditions that need correct diagnosis and treatment to protect both mother and baby.
26 citations
,
June 2012 in “The Journal of Obstetrics and Gynecology of India” Most skin changes during pregnancy are harmless and temporary, but some can risk the fetus and need careful treatment.
15 citations
,
May 1997 in “Annals of Internal Medicine” Tamoxifen caused hair loss in a 52-year-old woman.
6 citations
,
May 2016 in “British Journal of Dermatology” Botulinum toxin A effectively treated a man's facial cysts with no side effects and lasting results.
June 2023 in “Revista médica hondureña” Most pediatric cancer patients in the study developed skin problems, often due to their cancer treatment.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Higher fluence in hair removal damages hair follicles more, while lower fluence mimics natural hair regression, with long-term IPL treatments effectively reducing hair.
Proper care and understanding of skin diseases in pregnant women are crucial for their health and recovery.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
July 1994 in “Annals of Pharmacotherapy” Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
2 citations
,
January 2012 in “Journal of Clinical & Experimental Dermatology Research” Fexofenadine reduces discomfort but doesn't significantly improve hair regrowth in Alopecia Areata treatment.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
5 citations
,
February 2025 in “Pediatric Dermatology” Ritlecitinib was generally well tolerated in children with alopecia areata.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
February 2023 in “Reactions Weekly”
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.